The NIHR Imperial Biomedical Research Centre (BRC) aims to improve our understanding of the role of inflammatory mechanisms in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, traumatic brain injury, and stroke. Through this work, our team of world-class scientists is discovering disease mechanisms and risk factors that underpin new diagnostics and therapies for these conditions. Imperial […]
In Silico Drug Discovery
We are using a pioneering computational approach based on ‘causal reasoning’ to look in detail at the genetics involved in neurodegeneration. Success in this area has the potential to slow the progression of a number of degenerative disorders, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, through the use of therapies that restore healthy gene expression.
Traumatic Brain Injury
Our cutting edge PET and MRI brain imaging studies provide evidence of the mechanisms that lead to dementia, months or years after a person suffers a traumatic brain injury. We are applying this knowledge to provide early prognosis and tools to monitor brain health and support cognitive rehabilitation. A program to identify and test repurposed drugs that may reduce the incidence or severity of dementia following brain injury is ongoing.
Dementia
We are undertaking the first comprehensive evaluation of early pathological changes in people with Alzheimer’s disease and in those with strong clinical or lifestyle risk factors for the disease. PET scanning to identifies new markers of disease that can be visualized and complemented by MRI biomarker studies to form a new system for identifying early Alzheimer’s disease.
Stroke
We have made major progress in the use of anti-inflammatory treatment for stroke, and this work continues. We are now evaluating repurposed anti-inflammatory medications – in particular, natalizumab, a monoclonal antibody treatment used in multiple sclerosis. We are also testing, directly in humans, how initial inflammatory responses drive further brain damage in stroke.
In neurorehabilitation, we are developing remote sensors and therapeutic robotics and stimulation for stroke patients. Working with patients, our low cost devices for remote movement and balance monitoring, cognitive testing, and measurement of sleep quality and sustained attention are entering early clinical trials to support stroke recovery.
Multiple Sclerosis
Our main aim is to address the challenge of progressive multiple sclerosis, which is only delayed or marginally modified by current treatments. Our pre-clinical work on molecular strategies to modulate auto-immune damage is moving into humans for the first time. With this complete, we will be screening compound libraries for new drug repurposing and discovery of molecules with enhanced properties that could be therapeutic in progressive multiple sclerosis.
We host the Multiple Sclerosis and Parkinson’s Tissue Bank and associated molecular pathology programmes. We are also a lead centre for the Dementias Platform UK Imaging Network. We have collaborations with the Imperial College London Data Science Institute, UK Biobank, Human Connectome Project, and UCLH, as well as a number of pharmaceutical and healthcare companies, and individual Imperial College London engineers and physical scientists.
Key Individuals
-
Professor Paul Matthews
Theme Lead, Brain Sciences -
Dr Aldo Faisal
Senior Lecturer in Neurotechnology -
Dr Barry Seemungal
Consultant Neurologist -
Dr Claudia Clopath
Lecturer -
Dr David Owen
Clinical Senior Lecturer in Clinical Pharmacology -
Dr Enrico Petretto
Senior Lecturer -
Dr Kevin O'Neill
Consultant Neurosurgeon -
Dr Paolo Muraro
Clinical Reader in Neuroimmunology -
Dr Paresh Malhotra
Clinical Senior Lecturer / Consultant Neurologist -
Dr Paul Bentley
Senior Clinical Research Fellow & Consultant Neurologist -
Dr Paul Edison
Clinical Senior Lecturer -
Dr Paul Ramchandani
Reader in Child and Adolescent Psychiatry -
Dr Richard Nicholas
Consultant Neurologist -
Dr Richard Perry
Consultant neurologist -
Professor Anne Lingford-Hughes
Chair in Addiction Biology -
Professor David Brooks
Hartnett Professor of Neurology -
Professor David Dexter
Professor of Neuropharmacology -
Professor David Nutt
Edmond J Safra Chair in Neuropsychopharmacology -
Professor David Sharp
Professor of Neurology -
Professor Denis Azzopardi
Visiting Researcher -
Professor Etienne Burdet
Professor of Human Robotics -
Professor Michael Johnson
Professor of Neurology and Genomic Medicine -
Professor Paola Piccini
Professor of Neurology -
Professor Richard Festenstein
Clinical Professor of Molecular Medicine -
Professor Richard Reynolds
Professor of Cellular Neurobiology -
Professor Roger Gunn
Professor of Molecular Neuroimaging -
Professor Roland Veltkamp
Professor of Neurology/Chair of Stroke Medicine/Consultant -
Professor Simone Di Giovanni
Chair in Restorative Neuroscience
In Silico Drug Discovery
We are using a pioneering computational approach based on ‘causal reasoning’ to look in detail at the genetics involved in neurodegeneration. Success in this area has the potential to slow the progression of a number of degenerative disorders, including Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease, through the use of therapies that restore healthy gene expression.
Traumatic Brain Injury
Our cutting edge PET and MRI brain imaging studies provide evidence of the mechanisms that lead to dementia, months or years after a person suffers a traumatic brain injury. We are applying this knowledge to provide early prognosis and tools to monitor brain health and support cognitive rehabilitation. A program to identify and test repurposed drugs that may reduce the incidence or severity of dementia following brain injury is ongoing.
Dementia
We are undertaking the first comprehensive evaluation of early pathological changes in people with Alzheimer’s disease and in those with strong clinical or lifestyle risk factors for the disease. PET scanning to identifies new markers of disease that can be visualized and complemented by MRI biomarker studies to form a new system for identifying early Alzheimer’s disease.
Stroke
We have made major progress in the use of anti-inflammatory treatment for stroke, and this work continues. We are now evaluating repurposed anti-inflammatory medications – in particular, natalizumab, a monoclonal antibody treatment used in multiple sclerosis. We are also testing, directly in humans, how initial inflammatory responses drive further brain damage in stroke.
In neurorehabilitation, we are developing remote sensors and therapeutic robotics and stimulation for stroke patients. Working with patients, our low cost devices for remote movement and balance monitoring, cognitive testing, and measurement of sleep quality and sustained attention are entering early clinical trials to support stroke recovery.
Multiple Sclerosis
Our main aim is to address the challenge of progressive multiple sclerosis, which is only delayed or marginally modified by current treatments. Our pre-clinical work on molecular strategies to modulate auto-immune damage is moving into humans for the first time. With this complete, we will be screening compound libraries for new drug repurposing and discovery of molecules with enhanced properties that could be therapeutic in progressive multiple sclerosis.
We host the Multiple Sclerosis and Parkinson’s Tissue Bank and associated molecular pathology programmes. We are also a lead centre for the Dementias Platform UK Imaging Network. We have collaborations with the Imperial College London Data Science Institute, UK Biobank, Human Connectome Project, and UCLH, as well as a number of pharmaceutical and healthcare companies, and individual Imperial College London engineers and physical scientists.
